ABSTRACT
INTRODUCTION

63
Antibiotics are life-saving medications that represent one of the most important 64 advances of modern medicine. However, the ongoing emergence of organisms that are 4 The most successful and widely applied method to identify agents with 85 antibacterial activity has been whole-cell, bacterial growth assays. In this approach, 86 libraries of small molecules or natural products are screened for agents that limit 87 bacterial growth. However, growth-based assays have limitations (28, 37). For 88 example, the growth or no-growth readout has limited dynamic range. This is likely to as established biofilms and small colony-variants.
98
To address these limitations, we have developed a high throughput screen 99 (HTS)-compatible whole cell assay to detect agents that directly kill bacteria. The assay 100 is based on the release of intracellular adenylate kinase (AK) into culture medium as a 101 reporter of bacterial cell death. We show that the AK assay exhibits improved sensitivity 102 compared to conventional whole-cell growth assays and displays specificity for 103 bactericidal agents. Further, we establish that the assay can be used to screen for 104 agents that kill small colony-variant bacteria and bacteria within established biofilms.
105
To validate the AK assay as an HTS-compatible screening platform, we screened suggesting that they could be re-purposed as antimicrobials or serve as lead molecules following the death of the cell, will induce release of AK into the culture medium. 
295
Furthermore, the AK assay exhibited a dynamic range of nearly three-orders of 296 magnitude and excellent signal-to-noise.
297
The AK assay detects bactericidal molecules that are active against the ESKAPE 298 pathogens. Next, we examined the ability of the AK assay to detect the activity of Table 2) . We then performed the AK assay at 0, 
308
The MIC of colistin for this strain is 4 µg ml -1 , whereas AK release was robustly detected 309 at 0.25x, 0.5x and 1x the MIC value.
310
The MIC measures for each ESKAPE pathogen and each organism's 311 corresponding fold-increase in AK signal following treatment with 0.5x and 1.0x the MIC 312 concentration are provided in vancomycin had no effect on SCV viability at any concentration tested (data not shown)
389
and exhibited no change in AK release in comparison to mock treated cells (Fig. 4B) molecules was set at a 3-fold increase in extracellular AK activity corresponding to the 421 detection limit of statistically significant increases in AK activity for planktonic bacteria.
422
The hit rates for the different organisms ranged from 1.4% to 4.8%; a representative 423 example of raw screening data for Klebseilla pneumonaie is shown in Fig. 5B .
424
Screening results for all ESKAPE pathogens are summarized in Table S1 .
427
Consistent with expectations, a detailed assessment of the hits revealed that AK-
428
screening enriches for the identification of bactericidal compounds ( antibiotics within the Prestwick library by MIC testing (Table 2) , and this was also 452 observed by the AK-assay, indicating that the assay exhibits a low false-positive rate.
453
Interestingly, the assay also detected 38 drugs with no known antimicrobial properties
454
(denoted as "other" in Table 3 ) that were active against each organism; Supplemental
455
Table 2 provides a complete list of these compounds. 
476
Terfenadine and tamoxifen, which exhibited antimicrobial properties toward 477 planktonic S. aureus and E. faecium cells, respectively, were characterized further.
478
Terfenadine was evaluated for activity against S. aureus biofilms and small colony 479 variants using the AK assays described above. Treatment of 48 hr S. aureus strain
480
UAMS-1 biofilms with 10x MIC terfenadine elicited a modest 2.7-fold increase in AK 481 release (Fig. 6A) ; plating-based viability assays determined that this correlated with a 482 1.1 log reduction in biofilm cell viability (data not shown), which was comparable to the 483 activity of ciprofloxacin in the same assay conditions (Fig. 4A) . Similarly, treatment of fold increase in AK signal in comparison to mock treated cells (Fig. 6A) . Conventional
486
MIC testing subsequently verified that terfenadine is active against UAMS-1112 at 2 µg to members of the library with no previously reported antimicrobial activity.
551
We further studied the antimicrobial properties of two of these drugs in more 552 detail: terfenadine and tamoxifen. Terfenadine (Fig. 7A) is a non-sedating 553 antihistamine based on a 4-substituted piperdine scaffold that is also known to inhibit Furthermore, we found that terfenadine has activity against S. aureus small colony 564 variants and biofilms, properties not previously reported for this scaffold.
565
Our screen of E. faecium identified two structurally-related non-steroid estrogen 566 receptor antagonistis, tamoxifen and clomiphene ( Fig. 7 C & D) . Tamoxifen is used to 
